BeiGene, Ltd. (BGNE)
After hours:
- Zacks
Lilly (LLY) Gets Second FDA Nod for Lymphoma Drug Jaypirca
Following the latest approval, Lilly's (LLY) Jaypirca is the first and the only non-covalent BTK inhibitor to extend the benefit of targeting the BTK pathway.
- Zacks
Wall Street Analysts Think BeiGene, Ltd. (BGNE) Could Surge 44.28%: Read This Before Placing a Bet
The mean of analysts' price targets for BeiGene, Ltd. (BGNE) points to a 44.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
- Business Wire
BeiGene to Host ASH Investor Meeting in Person and via Webcast on December 10, 2023
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass., November 29, 2023--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that it will host an Investor Event at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego and via webcast at 8:00 PM PST on December 10, 2023. This event will cover BeiGene’s R&D progress and broad hematology portfolio, with invited speakers presenting key data from the ASH 2023.
